Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    ENP Newswire. February 26, 2024.